Trust Signals
Key Takeaways
- Gonadorelin is a 10-amino-acid synthetic GnRH peptide with a molecular weight of 1182.3 g/mol; it is structurally identical to endogenous GnRH, not an analog.
- Research-grade gonadorelin typically runs 20 to 60 USD per 2 mg vial; compounded pharmacy versions with full COA and sterility testing run higher, roughly 80 to 200 USD.
- Continuous, non-pulsatile dosing paradoxically suppresses LH and FSH by downregulating pituitary GnRH receptors, a failure mode most buyer guides never mention.
- The FDA's 2020 HCG reclassification drove a shift toward gonadorelin in TRT practice, but large randomized controlled trials in male hypogonadism management are still absent.
- A valid COA for injectable-grade material must include HPLC purity above 98 percent, mass-spec molecular weight confirmation, and endotoxin testing below 1 EU/mg.
What Is Gonadorelin and Should You Buy It?
Table of Contents
- What exactly is gonadorelin?
- Evidence ledger: what the data actually supports
- How does gonadorelin work? The mechanism with real numbers
- What does gonadorelin cost in 2026?
- What most gonadorelin pages get wrong
- Why storage rules matter: the chemistry behind peptide degradation
- Gonadorelin vs HCG vs kisspeptin: honest comparison
- Label and COA literacy: how to judge what you are buying
- Dosing and reconstitution table
- Side effects and contraindications
- Frequently Asked Questions
What Exactly Is Gonadorelin?
Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the entire hypothalamic-pituitary-gonadal (HPG) axis. The sequence is pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2, ten amino acids, with a pyroglutamate at the N-terminus and an amide at the C-terminus. This is not an analog; no amino acid is modified. That distinguishes it from GnRH agonist analogs like leuprolide, where position-6 substitutions dramatically increase receptor binding half-life and cause sustained suppression rather than pulsatile stimulation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The FDA approved gonadorelin hydrochloride (Factrel, Ayerst) in 1982 for diagnostic evaluation of hypothalamic-pituitary function and gonadorelin acetate (Lutrepulse, Ferring) in 1990 for ovulation induction via pulsatile pump. Neither brand is currently marketed in the US, but the compound remains legally manufacturable by licensed compounding pharmacies under USP Chapter 797.
Evidence Ledger: What the Data Actually Supports
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| Pulsatile gonadorelin raises LH and FSH in hypogonadotropic hypogonadism | Multiple RCTs, FDA-approved indication (Lutrepulse) | Positive, robust | High |
| Gonadorelin preserves testicular volume during TRT | Small observational studies, case series, mechanistic inference from HCG data | Positive, plausible | Low |
| Gonadorelin maintains intratesticular testosterone during TRT | Mechanistic extrapolation; no direct RCT in this population | Plausible, unproven | Very Low |
| Continuous dosing suppresses gonadotropins (paradoxical suppression) | Well-established mechanism; basis of FDA-approved GnRH agonist therapy | Suppressive if continuous | High |
| Gonadorelin is superior to HCG for fertility preservation on TRT | No head-to-head RCT; expert opinion only | Direction unclear | Very Low |
| Subcutaneous absorption adequate for pituitary stimulation | Pharmacokinetic studies in women, diagnostic use data | Positive | Moderate |
How Does Gonadorelin Work? The Mechanism with Real Numbers
Gonadorelin binds the GnRH receptor (GnRHR), a Gq/11-coupled GPCR expressed on pituitary gonadotroph cells. Receptor binding activates phospholipase C, generating IP3 and diacylglycerol, which mobilizes intracellular calcium and activates protein kinase C. The downstream result is exocytosis of preformed LH granules within minutes, followed by a slower FSH release that depends partly on de novo synthesis.
Key pharmacokinetic facts from clinical data: gonadorelin's plasma half-life is roughly 2 to 8 minutes after intravenous administration, rapid enzymatic degradation by endopeptidases cleaving the Tyr5-Gly6 and Pro9-Gly10 bonds. Subcutaneous administration extends effective exposure modestly; the peak LH surge typically occurs within 30 to 60 minutes of subcutaneous injection in clinical diagnostic protocols.
The pulsatile dosing requirement is not a preference; it is a biological necessity. Physiological GnRH is secreted in discrete pulses every 60 to 120 minutes. Continuous GnRH receptor occupancy triggers receptor internalization and downregulation, reducing gonadotroph sensitivity. This is the entire mechanism behind leuprolide and other GnRH agonist drugs used to achieve medical castration in prostate cancer. A gonadorelin protocol that doses too frequently will achieve the opposite of the intended goal.
What the mechanism does NOT prove: receptor activation in the pituitary does not guarantee clinically meaningful sperm production or intratesticular testosterone concentrations in men already on supraphysiological exogenous testosterone, because negative feedback from high circulating testosterone blunts downstream gonadotroph response. The signal competes with a strong hormonal brake.
What Does Gonadorelin Cost in 2026?
Pricing varies significantly by source type and documentation level.
| Source type | Typical price range | COA included? | Legal status for human use |
|---|---|---|---|
| Research chemical supplier | 20 to 60 USD per 2 mg vial | Sometimes (quality varies widely) | Gray zone; "not for human use" label |
| Licensed compounding pharmacy (with Rx) | 80 to 200 USD per 2 to 10 mg vial | Yes, with sterility and endotoxin data | Legal with valid prescription |
| Telemedicine TRT clinic (bundled) | 150 to 400 USD/month total protocol | Handled by pharmacy | Legal, supervised |
Price alone is a poor quality signal. A 25 USD research vial with no endotoxin testing carries unknown infectious risk if injected. The cost difference between research-grade and compounded pharmacy-grade largely reflects the cost of sterility testing, endotoxin assay, and regulatory compliance, not profit margin on the peptide itself.
What Most Gonadorelin Pages Get Wrong
Second omission: subcutaneous bioavailability. Gonadorelin's 2-to-8-minute plasma half-life after IV dosing extends modestly with subcutaneous injection, but the peptide is still rapidly degraded by local tissue peptidases. The fraction that reaches the portal blood supplying the anterior pituitary is not quantified in most TRT-context literature. Assuming full bioavailability equivalent to IV pulsatile delivery (the Lutrepulse pump mechanism) is not supported by available data.
Third omission: the regulatory pathway for HCG switched. The 2020 FDA guidance that removed HCG from the bulk drug substances list for compounding (503A pharmacies) did not ban HCG outright. It made it unavailable from most independent compounders. Some 503B outsourcing facilities may still supply it under specific circumstances. The gonadorelin-as-HCG-replacement narrative is partly accurate and partly market-driven; present it honestly.
Why Storage Rules Matter: The Chemistry Behind Peptide Degradation
Gonadorelin degradation follows two primary pathways. First, enzymatic hydrolysis: tissue endopeptidases cleave the peptide at predictable bond positions, particularly Tyr5-Gly6. At physiological pH and temperature this is fast, which is why the native peptide has a plasma half-life measured in minutes. In a vial, peptidase exposure is absent, but the second pathway dominates: chemical hydrolysis of amide bonds, which is pH and temperature dependent.
The amide bond hydrolysis rate increases sharply above neutral pH and accelerates roughly two-fold for every 10 degrees Celsius rise in temperature (a general rule for peptide bond hydrolysis, consistent with Arrhenius kinetics). This is why lyophilized (freeze-dried) powder is far more stable than reconstituted solution: removing water eliminates the hydrolysis substrate. Once you add bacteriostatic water, the clock starts. Refrigeration at 2 to 8 degrees C slows the reaction; room temperature storage of a reconstituted vial loses meaningful potency within days to weeks depending on exact pH and formulation.
Bacteriostatic water (containing 0.9 percent benzyl alcohol) is preferred over sterile water for reconstitution of multi-use vials because benzyl alcohol inhibits microbial growth, not because it stabilizes the peptide chemically. The peptide stability window is still determined by pH and temperature, not by the preservative. A vial reconstituted in bacteriostatic water and left at room temperature is not protected from chemical degradation.
Visual inspection is a partial check, not a guarantee. Aggregated or degraded gonadorelin may appear clear because the degradation products (short peptide fragments) remain in solution. Cloudiness or particulates are definitive signs of a problem; clarity is not a sign of quality.
Gonadorelin vs HCG vs Kisspeptin: Honest Comparison
| Factor | Gonadorelin | HCG | Kisspeptin |
|---|---|---|---|
| Mechanism level | Pituitary (GnRHR agonist) | Testis directly (LH receptor) | Hypothalamus (upstream of GnRH neurons) |
| FDA approval history | Yes (Factrel, Lutrepulse) | Yes (hypogonadism, cryptorchidism) | No; phase 1 to 2 trials only |
| Evidence in TRT fertility preservation | Mechanistically plausible; limited direct RCT | Strong mechanistic; some RCT data in male infertility | Very limited; research stage |
| Stimulates FSH? | Yes (pituitary FSH release) | Minimal (LH analog only) | Yes, via GnRH neuron stimulation |
| Compounding availability (US) | Available via 503A with Rx | Restricted since 2020 FDA guidance | Limited; niche compounders |
| Desensitization risk | Yes, high if continuous dosing | Lower; acts downstream of pulsatile requirement | Yes, potentially; not well characterized |
| Estradiol elevation risk | Moderate (via increased testicular T) | Higher (direct testicular stimulation) | Unknown in this context |
| Where gonadorelin loses | Loses on direct testicular evidence vs HCG; loses on convenience (frequent dosing required) | N/A | |
The honest verdict: HCG has a stronger evidence base for maintaining intratesticular testosterone because it acts directly at the Leydig cell LH receptor, bypassing the need for pulsatile pituitary signaling. Gonadorelin's regulatory advantage is that it is currently more accessible through US compounders. If HCG were equally accessible, it would be the evidence-superior choice for most TRT fertility-preservation protocols. This is a market access story as much as a pharmacology story.
Label and COA Literacy: How to Judge What You Are Buying
When you buy gonadorelin peptide for sale from any source, request and read the certificate of analysis before use. A minimum-quality COA for injectable-grade material must include:
| Test | Minimum acceptable result | Why it matters |
|---|---|---|
| HPLC purity | Above 98 percent area under curve | Confirms the majority of mass is correct peptide, not synthesis byproducts |
| Mass spectrometry (MS) | Molecular ion matching 1182.3 g/mol (free acid) or 1302.4 g/mol (acetate salt) | Confirms identity; HPLC alone cannot rule out co-eluting impurities of similar size |
| Endotoxin (LAL test) | Below 1 EU/mg for injectable use | Gram-negative bacterial endotoxins cause fever and sepsis even in sterile preparations |
| Sterility or bioburden | Sterile (no growth in culture) for injectable; bioburden limit for non-injectable | Research-grade vials often lack this test; compounded pharmacy vials require it under USP 71 |
| Water content (Karl Fischer) | Below 6 percent for lyophilized material | High residual water accelerates degradation in the vial |
A COA that lists only HPLC purity and nothing else is inadequate for injectable-grade assessment. Many research-chemical suppliers provide exactly this, and nothing more.
Dosing and Reconstitution: Practical Numbers
The following table reflects clinical and published protocol ranges. It is not a prescribing recommendation.
| Use context | Typical dose | Frequency | Route | Evidence basis |
|---|---|---|---|---|
| Diagnostic pituitary stimulation test | 100 mcg | Single dose | IV or SQ | FDA-approved Factrel protocol |
| Ovulation induction (historical Lutrepulse) | 5 mcg per pulse IV or 20 mcg per pulse SQ | Every 90 minutes via pump | IV or SQ pump | FDA-approved Lutrepulse protocol |
| TRT adjunct (clinical practice, off-label) | 100 mcg per injection | 2 to 3 times per week | SQ | Expert consensus, case series; no RCT |
Reconstitution math for a 2 mg vial: add 2.0 mL bacteriostatic water to yield 1 mg/mL (1000 mcg/mL). A 100 mcg dose is drawn as 0.1 mL (10 units on a 100-unit insulin syringe). Label the vial with the reconstitution date and discard after 28 days if refrigerated.
Side Effects and Contraindications
From the FDA-approved Factrel and Lutrepulse prescribing data: the most commonly reported adverse effects were injection-site reactions (redness, swelling, pain), headache, nausea, and light-headedness. Systemic hypersensitivity reactions including anaphylaxis were reported rarely with repeated dosing. Ovarian hyperstimulation syndrome (OHSS) is a documented risk in women undergoing ovulation induction and can be life-threatening in severe cases.
In the male TRT-adjunct context, the side effect profile at low subcutaneous doses has not been characterized in large controlled trials. Theoretical risks include transient LH and FSH surges, possible mood changes if androgen fluctuations occur, and injection-site reactions. The estradiol elevation risk is lower than with HCG because gonadorelin's effect on Leydig cell function is indirect and time-limited by the peptide's rapid clearance.
Contraindications from FDA labeling include known hypersensitivity to gonadorelin and any condition exacerbated by sex hormone stimulation (e.g., hormone-sensitive cancers). Use in pregnancy requires the ovulation-induction context with close monitoring; off-label male use has no FDA-defined contraindication list beyond hypersensitivity.
Frequently Asked Questions
What is gonadorelin and how does it differ from GnRH?
Gonadorelin is synthetic GnRH, an identical 10-amino-acid decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) to endogenous gonadotropin-releasing hormone. When dosed in brief pulses it stimulates pituitary LH and FSH release. The name difference is regulatory, not structural.
What is the typical gonadorelin price per vial in 2026?
Research-grade gonadorelin typically costs roughly 20 to 60 USD per 2 mg vial, depending on supplier and quantity. Compounded pharmacy versions prescribed through a clinic are usually higher, ranging from 80 to 200 USD per vial, but come with certificate-of-analysis documentation and sterility testing.
Is gonadorelin the same as Factrel or Lutrepulse?
Yes. Factrel (Ayerst) and Lutrepulse (Ferring) are brand names for gonadorelin hydrochloride and gonadorelin acetate respectively. Both are the same 10-amino-acid GnRH peptide. Lutrepulse was delivered via pulsatile pump for ovulation induction; Factrel was used diagnostically.
How is gonadorelin used alongside testosterone replacement therapy?
Clinicians prescribe subcutaneous gonadorelin, typically 100 mcg two to three times weekly, to maintain pulsatile LH and FSH signaling during TRT. This approach aims to preserve testicular volume and intratesticular testosterone production, supporting fertility preservation while on exogenous testosterone.
Why is gonadorelin replacing HCG in some TRT protocols?
The FDA's 2020 removal of HCG from the drug shortage list led compounding pharmacies to stop making it legally for off-label TRT use. Gonadorelin acts upstream at the pituitary rather than directly mimicking LH at the testis, and remains accessible through licensed compounders, making it a practical substitute.
What does gonadorelin degradation look like, and how should it be stored?
Lyophilized gonadorelin is stable at room temperature for a limited period, but once reconstituted in bacteriostatic water it should be refrigerated at 2 to 8 degrees C and used within 28 days. A degraded solution may show visible particulates or cloudiness. Peptide bond hydrolysis accelerates sharply above pH 7 and at warm temperatures.
Can gonadorelin cause desensitization with frequent dosing?
Yes. Continuous or high-frequency gonadorelin administration downregulates pituitary GnRH receptors, suppressing LH and FSH, the same mechanism used intentionally in GnRH agonist therapy for prostate cancer. Pulsatile dosing, typically every 60 to 90 minutes physiologically or every 2 to 3 days in TRT protocols, is required to avoid paradoxical suppression.
How do I read a gonadorelin COA to verify purity?
Look for HPLC purity above 98 percent, mass spectrometry confirmation of the correct molecular weight (1182.3 g/mol for the free acid form), endotoxin testing below 1 EU/mg, and sterility or bioburden data if injectable use is intended. A COA lacking MS confirmation or endotoxin data is incomplete for injectable-grade material.
What are the documented side effects of gonadorelin?
In clinical trials for ovulation induction, the most common adverse effects were injection-site reactions, headache, and nausea. Rare but serious risks include ovarian hyperstimulation syndrome in females and anaphylaxis. In TRT-adjacent male use at low subcutaneous doses, the reported side effect profile is modest, though large controlled trials in this population are absent.
Is buying gonadorelin for research legal?
In the United States, selling peptides labeled "for research use only, not for human consumption" exists in a regulatory gray zone. The FDA does not approve this framing as a workaround for human use. Compounded gonadorelin obtained via a licensed prescriber and compounding pharmacy is the legally clear pathway for individual human use.
How does gonadorelin compare to kisspeptin for HPG axis support?
Kisspeptin acts one step upstream of gonadorelin, stimulating hypothalamic GnRH neurons rather than the pituitary directly. Gonadorelin has decades of clinical evidence including approved indications. Kisspeptin research is growing but remains largely in academic phase 1 to 2 trials. Gonadorelin wins on evidence depth; kisspeptin may offer a more physiological stimulation pattern.
What concentration and vial size should I look for when buying gonadorelin?
Compounded gonadorelin is most commonly supplied as 2 mg or 10 mg lyophilized powder per vial. A typical reconstitution target for TRT use is 1 mg per mL using bacteriostatic water, yielding 100 mcg per 0.1 mL injection. Confirm the vial size, fill weight, and diluent type before calculating your dose.
Sources
- FDA prescribing information: Factrel (gonadorelin hydrochloride) injection. Wyeth-Ayerst Laboratories. Original approval 1982. Available via FDA Drugs@FDA.
- FDA prescribing information: Lutrepulse (gonadorelin acetate) for injection. Ferring Pharmaceuticals. Original approval 1990. Available via FDA Drugs@FDA.
- Millar RP, et al. "Gonadotropin-releasing hormone receptors." Endocrine Reviews. 2004;25(2):235-275. PMID 15082521.
- Conn PM, Crowley WF Jr. "Gonadotropin-releasing hormone and its analogues." New England Journal of Medicine. 1991;324(2):93-103. PMID 1984193.
- Crowley WF Jr, et al. "The biologic activity of a more potent analog of gonadotropin-releasing hormone in normal and gonadotropin-deficient subjects." New England Journal of Medicine. 1980;302(19):1052-1057. PMID 6967715.
- FDA. "Memorandum: List of Bulk Drug Substances That May Be Used in Pharmacy Compounding Under Section 503A." 2020. Docket FDA-2013-N-0523.
- USP Chapter 797: Pharmaceutical Compounding -- Sterile Preparations. United States Pharmacopeia and National Formulary. Current edition.
- Handelsman DJ, Conway AJ, Boylan LM. "Pharmacokinetics and pharmacodynamics of testosterone pellets in man." Journal of Clinical Endocrinology and Metabolism. 1990;71(1):216-222. PMID 2164650. (Referenced for context on HPG axis suppression during TRT.)
- Chan AC, et al. "Kisspeptin and the hypothalamic control of reproduction: lessons from the human." Endocrinology. 2011;152(7):2540-2550. PMID 21521751.
- Manning M, et al. "Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics." Journal of Neuroendocrinology. 2012;24(4):609-628. (Referenced for peptide stability and degradation principles.)